Most sites still open for biotech clinical activity across Asia-Pacific

Many locations across Asia-Pacific, especially Australia, South Korea, Hong Kong or Taiwan, appear to be managing the crisis well. Sites have changed how they manage trials in line with the most recent health guidelines and a majority are still able to deliver the clinical trial services for biotechnology companies.

Novotech has recently released detailed reviews on the current status of clinical trials in the Asia-Pacific region during the global COVID-19 crisis. This data highlighted that most sites in the region are adapting well to the crisis and are still open for clinical activity and many sites are still very interested in new studies.

In South Korea and Taiwan for example, site initiation, patient recruitment, onsite monitoring and participant visits are proceeding normally across the major biotech sites.

Novotech helps accelerates infectious disease trials in Asia-Pacific

Novotech’s model relies on having experienced local leadership and strong relationships with investigators and sites in the region. Ultimately this benefits biotechnology companies and allows them to accelerate clinical studies.

Novotech undertakes a large number of infectious diseases trials and has strong relationships in this area. Novotech has conducted over 200 projects in infectious diseases and vaccines. Many biotechnology companies look at the Asia-Pacific region for their trials in infectious diseases and vaccines due to the high incidence of conditions such as Hepatitis, HIV and Influenza and other infection types across the region.

Asia-Pacific is recognized by clinical phase biotechnology companies for accelerated patient enrolment especially in rare diseases, metabolic conditions, oncology, immuno-oncology and infectious diseases, and lower clinical research costs.